Results 61 to 70 of about 8,937 (172)
Background: Chronic lymphocytic leukemia (CLL) remains an incurable disease with variable course. It is typically responsive to several courses of chemotherapy.
Waseem F Al Tameemi
doaj
Thitima Kongnakorn,1 James A Sterchele,2 Christopher G Salvador,3 Denis Getsios,4 Mkaya Mwamburi51Evidera, Bangkok, Thailand; 2formerly of Teva Branded Pharmaceutical Products R&D, Inc, Frazer, PA, 3Oncology Market Research, Teva Branded ...
Kongnakorn T +4 more
doaj
In spite of the many available protocols, the use of chemotherapy for the management of canine mast cell tumours (MCT) remains empirical, and there is lack of criteria for the choice of protocol and definition of patients who may benefit from treatment ...
R.S. Horta +5 more
doaj +1 more source
Theragnostic platforms, which integrate therapeutic and diagnostic capabilities, have gained significant interest in drug research because of to their potential advantages.
Thi Ngoc Han Pham +7 more
doaj +1 more source
Theragnostics has become a popular term nowadays, since it enables both diagnosis and therapy at the same time while only using one carrier platform.
Phuong-Thao Dang-Luong +5 more
doaj +1 more source
Luis Felipe Casado,1 Amparo Burgos,2 Eva González-Haba,3 Javier Loscertales,4 Tania Krivasi,5 Javier Orofino,6 Carlos Rubio-Terres,7 Darío Rubio-Rodríguez7 1Hematology Department, Hospital Virgen de la Salud, Toledo, Spain; 2Pharmacy
Casado LF +7 more
doaj
Orelabrutinib is a potent, irreversible, and highly-selective BTK inhibitor that has been approved for the treatment of relapsed/refractory chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL). This randomized, phase 3 study (ClinicalTrials.
Fei Li +50 more
doaj +1 more source
Chlorambucil is used in veterinary medicine for various cancers, while Toceranib, which was licenced for treating canine mast cell tumours, is now used against other solid tumours.
Yuk-Yin Lai +3 more
doaj +1 more source
Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Lukáš Smolej 4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech
Smolej L
doaj

